Швейцарія - італійська - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - bicalutamidum - compresse rivestite con film - bicalutamidum 150 mg, cellulosum microcristallinum, povidonum k 30, carmellosum natricum conexum, natrii laurilsulfas, lactosum monohydricum 105 mg, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, polydextrosum, e 171, macrogolum 4000, pro compresso obducto corresp. natrium 9.582 mg. - prostatico - synthetika

Швейцарія - італійська - Swissmedic (Swiss Agency for Therapeutic Products)

medius ag - bicalutamidum - compresse rivestite con film - bicalutamidum 50 mg, lactosum monohydricum 61 mg, carboxymethylamylum natricum a corresp. natrium 0.315 mg, povidonum k 29-32, magnesii stearas, Überzug: hypromellosum, macrogolum 300, e 171, pro compresso obducto. - prostatico - synthetika

Швейцарія - італійська - Swissmedic (Swiss Agency for Therapeutic Products)

medius ag - bicalutamidum - compresse rivestite con film - bicalutamidum 150 mg, lactosum monohydricum 183 mg, carboxymethylamylum natricum a corresp. natrium 0.945 mg, povidonum k 29-32, magnesii stearas, Überzug: hypromellosum, macrogolum 300, e 171, pro compresso obducto. - prostatico - synthetika

Європейський Союз - італійська - EMA (European Medicines Agency)

amryt pharmaceuticals dac - lomitapide - ipercolesterolemia - agenti modificanti i lipidi - lojuxta è indicato come coadiuvante di una dieta low‑fat e altri medicinali lipid‑lowering con o senza il apheresis di lipoproteina a bassa densità (ldl) in pazienti adulti con ipercolesterolemia familiare omozigote (hofh). genetica conferma di hofh dovrebbe essere ottenuto ogni volta che è possibile. altre forme di primaria hyperlipoproteinaemia e cause secondarie di ipercolesterolemia (e. sindrome nefrosica, ipotiroidismo) deve essere esclusa.

Європейський Союз - італійська - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - degarelix - neoplasie prostatiche - terapia endocrina - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Європейський Союз - італійська - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamide - neoplasie prostatiche - terapia endocrina - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Швейцарія - італійська - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - goserelinum - fertigspritze mit implantat - goserelinum 3.6 mg ut goserelini acetas, poly(lactidum-co-glycolidum) pro praeparatione. - prostata-ca,agg.ther.prostata-ca,mamma-ca,agg.ther.frühes mamma-ca,endometriose,uterusmyom,ablazione,ass.repro.med. - biotechnologika

Швейцарія - італійська - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - goserelinum - fertigspritze mit implantat - goserelinum 10.8 mg ut goserelini acetas, poly(lactidum-co-glycolidum) pro praeparatione. - prostatico,l'endometriosi,la fase preoperatoria.i trattamenti.v.fibroma uterino anämischer pazienti in komb.con una terapia marziale - biotechnologika

Швейцарія - італійська - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - bicalutamidum - filmtabletten - bicalutamidum 50 mg, pro compresso obducto. - prostatakarzinom - synthetika human

Швейцарія - італійська - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - bicalutamidum - filmtabletten - bicalutamidum 150 mg, pro compresso obducto. - prostatakarzinom - synthetika human